Related Experiment Videos
[Malignant neuroleptic syndrome after haloperidol administration]
M U Gerbershagen1, W D Ito, F Wappler
1Klinik für Anästhesiologie, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg. gerbershagen@uke.uni-hamburg.de
Der Anaesthesist
|June 22, 2001
Summary
Neuroleptic Malignant Syndrome (NMS) is a rare antipsychotic complication. This case highlights NMS symptoms, intensive care, and recovery, emphasizing differential diagnosis for patient safety.
Area of Science:
- Neuroscience
- Pharmacology
- Critical Care Medicine
Background:
- Neuroleptic Malignant Syndrome (NMS) is a rare but life-threatening complication associated with antipsychotic medications.
- Early recognition and prompt management are crucial for patient outcomes.
Observation:
- A 65-year-old patient developed NMS during treatment for a severe depressive episode with psychotic symptoms, exhibiting hyperthermia, rigidity, elevated creatine phosphokinase, leukocytosis, liver enzymes, reduced consciousness, and autonomic disturbances.
- The patient also developed secondary pneumonia, potentially linked to chest wall rigidity.
Findings:
- Intensive care involved immediate discontinuation of the causative agent, supportive therapy (rehydration, catecholamines), and dantrolene administration.
- The patient recovered fully after 23 days of intensive treatment, with normalization of all pathological parameters.
Implications:
- This case underscores the importance of recognizing NMS symptoms and initiating prompt, intensive care.
- Understanding NMS pathogenesis theories and differential diagnoses, including malignant hyperthermia and serotonin syndrome, is vital for effective clinical management.